PYXS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Pyxis Oncology Inc (PYXS) is not a strong buy at the moment for a beginner investor with a long-term focus. The stock shows weak technical indicators, no significant trading signals, and mixed financial performance. While the company has promising developments in its pipeline, its financials and recent analyst sentiment suggest a cautious approach.
The technical indicators for PYXS are bearish. The MACD histogram is negative and expanding, RSI is neutral at 37.097, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 1.382, with resistance at 1.649. No clear upward momentum is observed.
These factors indicate some operational stability and potential for future growth.
The company reported a widened net loss of $79.6 million for FY2025, a revenue decline of 13.7% YoY in Q4, and missed EPS expectations. Gross margin dropped significantly by 19.26% YoY. Additionally, the stock shows no significant insider or hedge fund activity, and technical indicators remain weak.
In Q4 2025, revenue remained flat YoY at $11.038 million, net income dropped by 49.10% YoY to -$18.106 million, and EPS decreased by 50% YoY to -$0.29. Gross margin also declined by 19.26% YoY to 78.37%.
Stifel recently lowered its price target from $9 to $8 while maintaining a Buy rating, citing revised financing assumptions. Analysts are encouraged by the company's progress in its Phase 1 dose expansion study but remain cautious due to financial challenges.
